urea breath test

urea breath test
Name	Urea breath test
Purpose	Detection of Helicobacter pylori infection

urea breath test. The urea breath test is a non-invasive diagnostic procedure primarily used to detect the presence of the bacterium Helicobacter pylori in the stomach, which is a major cause of peptic ulcer disease and gastric cancer. It operates by measuring labeled carbon dioxide in a patient's breath after ingestion of a substrate containing isotopes of carbon. This test is widely endorsed by medical societies like the American College of Gastroenterology due to its high accuracy and is often employed following treatments like triple therapy to confirm eradication.

Medical uses

The primary application is for diagnosing active Helicobacter pylori infection, a pathogen strongly associated with conditions such as duodenal ulcer and gastric mucosa-associated lymphoid tissue lymphoma. It is recommended in clinical guidelines from the Maastricht Consensus Report for both initial diagnosis and as a test of cure after antimicrobial therapy involving drugs like amoxicillin and clarithromycin. The test is also utilized in screening protocols within populations with high prevalence of gastric cancer, as identified in studies from institutions like the National Institutes of Health. Its non-invasive nature makes it preferable to endoscopic procedures like gastroscopy for many patients.

Procedure

The patient is required to fast, typically for at least four hours prior to the test, to ensure an empty stomach. A baseline breath sample is collected by having the patient exhale into a container, such as a Vacutainer. The patient then ingests a prepared solution containing urea labeled with either the non-radioactive isotope carbon-13 or the radioactive isotope carbon-14; the use of carbon-14 is regulated by bodies like the Nuclear Regulatory Commission. After a waiting period, usually 10 to 30 minutes, a second breath sample is collected. The samples are then analyzed using instrumentation like isotope ratio mass spectrometry or a scintillation counter to measure the ratio of labeled carbon dioxide.

Interpretation of results

A positive result indicates the presence of urease enzyme produced by Helicobacter pylori, as the bacterium metabolizes the labeled urea into carbon dioxide that is detected in the breath. The cutoff values for positivity, often expressed as delta over baseline values, are established through clinical trials referenced by organizations like the Food and Drug Administration. A negative result suggests the absence of active infection, which can be crucial for ruling out Helicobacter pylori as a cause of symptoms in diseases like functional dyspepsia. False negatives can occur with recent use of medications like proton pump inhibitors or antibiotics, necessitating a washout period as advised by the American Gastroenterological Association.

Mechanism

The test exploits the high urease activity of Helicobacter pylori, an enzyme not produced by human cells in the stomach. Upon ingestion, the labeled urea reaches the gastric lumen where, if the bacterium is present, its urease catalyzes hydrolysis into ammonia and labeled carbon dioxide. This carbon dioxide is rapidly absorbed into the bloodstream, transported to the lungs, and exhaled. The detection of the isotopic label in the breath, using technologies developed from principles in nuclear chemistry, provides a direct measure of bacterial metabolic activity. This biochemical principle was first demonstrated in research at places like the University of Virginia.

History and development

The discovery of Helicobacter pylori by Barry Marshall and Robin Warren in the early 1980s, for which they received the Nobel Prize in Physiology or Medicine, necessitated reliable diagnostic methods. Early breath test prototypes using carbon-14 urea were developed by researchers including David Graham at the Baylor College of Medicine. Subsequent refinement introduced the safer carbon-13 version, popularized through collaborations with companies like Merck & Co. for widespread clinical use. Its adoption was accelerated by pivotal studies presented at forums like the Digestive Disease Week conference and endorsements from the Centers for Disease Control and Prevention.

Limitations and alternatives

Limitations include potential false negatives due to concomitant use of bismuth subsalicylate or recent antimicrobial therapy, and it does not provide visual assessment of the gastric mucosa like endoscopy. Geographic variations in Helicobacter pylori strains, as studied in regions like East Asia, can also influence test performance. Primary alternatives include the stool antigen test, endorsed by the European Helicobacter and Microbiota Study Group, and invasive methods like histological examination of biopsies obtained during esophagogastroduodenoscopy. Serological tests for antibodies, though available, are less preferred for active infection diagnosis by guidelines from the Japanese Society of Gastroenterology.

Category:Medical tests Category:Gastroenterology